Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT COMPLETION OF THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that, the phase III clinical trial of OT-702 (aflibercept intravitreous injection, EYLEA® biosimilar) has been successfully completed in China. OT-702 was co-developed by the Group and its partner Shandong Boan Biotechnology Co., Ltd. (山東博安生物技術股份有限公司) ("**Boan Bio**"), the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 6955). The phase III clinical trial of OT-702 was jointly conducted by both parties, and its new drug application (NDA) will be submitted to the Center for Drug Evaluation of National Medical Products Administration of China (中國國家藥品監督管理局藥品審評中心) in the near future.

Pursuant to the cooperation and exclusive promotion agreement entered into by both parties in October 2020, the Group, together with Boan Bio, shall co-advance the phase III clinical trial of OT-702, and the Group was granted the exclusive right to promote and commercialize the product in mainland China.

OT-702 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection. As a biosimilar to EYLEA® (aflibercept intravitreous injection), OT-702 is indicated for the treatment of patients with neovascular wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), choroidal neovascularization (CNV) and retinopathy of prematurity (ROP) in pathological myopia. As a soluble trapping receptor, OT-702 can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases.

The completed pre-clinical head-to-head comparison study of OT-702 to EYLEA® (aflibercept intravitreous injection) showed OT-702 shared a high degree of similarity in both physical and chemical properties and biological activities with EYLEA®. The results of its phase I clinical trial showed that OT-702 has a good safety and tolerability profile. The completed phase III clinical trial of OT-702 is a randomized, double-blind, parallel-controlled and multicenter clinical study to compare the efficacy and safety of OT-702 to EYLEA® in the treatment of wet age-related macular degeneration. The results of this clinical trial demonstrated clinically significant improvement in the eye's best corrected visual acuity (BCVA) under study at 24 weeks compared with the baseline (by using the early treatment of diabetic retinopathy study (ETDRS) visual acuity chart) for both groups of patients subject to the clinical trial to an equivalent extent.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-702 (aflibercept intravitreous injection, EYLEA® biosimilar) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, April 8, 2024

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.